Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGONCALVES, Ruben
dc.contributor.authorLABADIE, Magali
dc.contributor.authorCHOURAQUI, Simon
dc.contributor.authorPEYRE, Alexandre
dc.contributor.authorCASTAING, Nadege
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDAVELUY, Amelie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOLIMARD, Mathieu
dc.date.accessioned2022-01-20T10:32:41Z
dc.date.available2022-01-20T10:32:41Z
dc.date.issued2021-12-01
dc.identifier.issn1556-9519 (Electronic) 1556-3650 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/124450
dc.description.abstractEnBACKGROUND AND AIMS: MDMB-4en-PINACA is a synthetic cannabinoid receptor agonist (SCRA) that has recently emerged. Data regarding clinical presentations in the event of intoxication is scarce. This study presents MDMB-4en-PINACA identification in cannabis consumers with clinical and analytical descriptions. METHODS: Between November 2020 and March 2021, all patients with unexpected or unusually severe effects and Poisoning Severity Score (PSS) greater than or equal to 2 after cannabis consumption were included. Blood and/or urine samples were collected for toxicological analysis. When available, drug material samples were also collected for analysis. RESULTS: Between November 2020 and March 2021, 13 patients were included. All cases typically presented with altered mental status (n = 13), and nearly all had returned to a normal or quasi-normal state after around 11 h of observation. Neurological symptoms included headaches (n = 3), hallucinations (3), mydriasis (3), amnesia (2) and seizures (5). Psychiatric symptoms were paranoia (6) and anxiety (2). Digestive symptoms were nausea (2) and vomiting (6). No deaths were recorded. All patients were positive for the SCRA MDMB-4en-PINACA in urine, blood and/or drug material sample. Results from toxicology testing paired with case history showed the potential for MDMB-4en-PINACA to cause or contribute to different clinical disorders. Conclusions: This study highlights the risk of intoxication by SCRAs when taking low-THC cannabis products. Forensic scientists, public health and public safety officials, law enforcement personnel and clinicians should be aware of the impact that these emergent SCRAs may have in their work, especially MDMB-4en-PINACA.
dc.language.isoENen_US
dc.subject.enMDMB-4en-PINACA
dc.subject.enSynthetic cannabinoid receptor agonist
dc.subject.enLC-QTOF
dc.subject.enCannabis
dc.subject.enIntoxication
dc.subject.enCannabidiol
dc.title.enInvoluntary MDMB-4en-PINACA intoxications following cannabis consumption: clinical and analytical findings
dc.typeArticle de revueen_US
dc.identifier.doi10.1080/15563650.2021.1994144en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34850659en_US
bordeaux.journalClinical Toxicologyen_US
bordeaux.page1-6en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03537115
hal.version1
hal.date.transferred2022-01-20T10:32:43Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Toxicology&rft.date=2021-12-01&rft.spage=1-6&rft.epage=1-6&rft.eissn=1556-9519%20(Electronic)%201556-3650%20(Linking)&rft.issn=1556-9519%20(Electronic)%201556-3650%20(Linking)&rft.au=GONCALVES,%20Ruben&LABADIE,%20Magali&CHOURAQUI,%20Simon&PEYRE,%20Alexandre&CASTAING,%20Nadege&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée